Core Viewpoint - The company Norland announced that its subsidiary, Beijing Huienland Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of its generic drug "Cyclosporine Eye Drops (II)" at a concentration of 0.05%, aimed at treating dry eye syndrome by promoting tear secretion [2]. Group 1 - The approval allows the company to initiate clinical trials for the eye drop product [2]. - The product is specifically designed to address dry eye syndrome, which is a significant market in ophthalmology [2].